recognized standard clinical outcome assessment. In March: Tiziana announced a publication in the preeminent1 journal, Proceedings of the National Academy of Sciences , that. | April 26, 2023
Exhibit 99.1 Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer s Disease to be Presented by Dr. Howard Weiner at the International. | March 31, 2023
Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer's disease (AD)Modulation of neuroinflammation may be synergistic to existing treatments in AD NEW
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that positive data from a study of intranasal anti-CD3 monoclonal antibody (mAb) in an animal model of.